Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Oncotelic Therapeutics Inc (OTLC)

OTC Markets
Currency in USD
Disclaimer
0.0411
+0.0001(+0.24%)
Closed

OTLC Comments

$Oncotelic Therapeutics Inc Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments $OTLC https://www.benzinga.com/partner/biotech/24/02/37210624/oncotelic-therapeutics-shares-groundbreaking-discovery-in-pediatric-brainstem-tumors-demonstratin
Oncotelic Announces Release of Pet2DAO Tokens (PDAO): https://www.benzinga.com/pressreleases/23/04/g31629187/oncotelic-announces-release-of-pet2dao-tokens-pdao
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID: https://www.yahoo.com/now/oncotelic-awarded-barda-funding-development-110000810.html
Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers: https://oncotelic.irpass.com/Oncotelic-Announces-Successful-Completion-of-the-Safety-Evaluation-of-a-TGF-946--Inhibitor--OT-101--and-IL-2--Aldesleukin--in-Phase-1-Combination-Trial-in-Solid-Tumor-Cancers-11-16-2021
ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION:https://oncotelic.irpass.com/ONCOTELIC-ACQUIRES-FAST-TO-MARKET-LATE-STAGE-DRUG-CANDIDATE-FOR-PARKINSON-DISEASE--ERECTILE-DYSFUNCTION--AND-FEMALE-SEXUAL-DYSFUNCTION--10-4-2021
OT-101 – an antisense against TGF-β2 – for the treatment of solid tumors with focus on brain cancer in adult and DIPG in children. RPD for pediatric DIPG granted by US FDA. OT-101, also referred to Trabedersen, is a novel antisense oligodeoxynucleotide (ODN) developed by Oncotelic for the treatment of patients with pancreatic carcinoma, malignant melanoma, colorectal carcinoma, high-grade glioma (HGG), and other transforming growth factor beta 2 (TGF-β2) overexpressing malignancies (e.g., prostate carcinoma, renal cell carcinoma, etc.).
ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION: https://oncotelic.irpass.com/ONCOTELIC-TO-ACQUIRE-LATE-STAGE-DRUG-CANDIDATE-FOR-PARKINSON-DISEASE--ERECTILE-DYSFUNCTION--AND-FEMALE-SEXUAL-DYSFUNCTION--9-1-2021
ONCOTELIC AND GOLDEN MOUNTAIN PARTNERS FORMING A JOINT VENTURE FOR IPO:https://finance.yahoo.com/news/oncotelic-golden-mountain-partners-forming-110000184.html
This is at the level in which people that bought OCGN and BNGO got rich.
MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™: https://finance.yahoo.com/news/mateon-partnered-chopra-foundation-artiveda-145200742.html
Targeting TGF-b pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19: https://www.medrxiv.org/content/10.1101/2021.01.24.21250418v1
MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT: https://finance.yahoo.com/news/mateon-launching-mobile-app-artihealth-120000766.html
Zacks Small Cap Research: MATN: POSITIVE INTERIM RESULTS FOR ARTIVEDATM; WILL APPROACH FDA FOR EUA...: https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2021/MATN-Positive-Interim-Results-for-ARTIVedaTM-Will-Approach-FDA-for-EUA/default.aspx
Litchfield Hills Research MATN-Buy-$3 PT: http://www.hillsresearch.com/wp-content/uploads/2021/01/MATN-OT-101-treats-first-patient.pdf
We might need to redefine our approach to drug discovery and approval to be prepared for the future: https://www.expresspharma.in/market-pharma/we-might-need-to-redefine-our-approach-to-drug-discovery-and-approval-to-be-prepared-for-the-future/
Initiating coverage of Mateon Therapeutics, Inc, with a Buy rating and $3 PT: https://www.hillsresearch.com/current-research/
Positive early results for artivedatm in treating COVID-19: https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2020/MATN-Positive-Early-Results-for-ARTIVedaTM-in-Treating-COVID-19/default.aspx
good step moving forward. good place to be in now
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.